Musk received an ultimatum from the SEC or faced multiple accusations, and the long-term confrontation between the US SEC and Musk escalated again. On December 12th, local time, Alex spiro, a lawyer of Musk, wrote to Gary Gensler, the outgoing chairman of the SEC, accusing the agency of launching an "ulterior motive action" against Musk, and revealed that the SEC had restarted the investigation of Neuralink, a brain-computer interface company owned by Musk. According to the contents of the letter, the SEC asked Musk to accept the settlement agreement within 48 hours and pay the fine, otherwise he would face "multiple accusations". These allegations are related to Musk's stock investment behavior before the acquisition of Twitter (now "X") in 2022, involving trading time and the legality of information disclosure. It was mentioned in the letter that the accusation originated from an investigation that lasted for several years, and the SEC recently issued a subpoena to Musk's lawyer, asking him to provide testimony. Alex spiro said that he had explicitly refused to cooperate and accused the agency of "political motives". Musk also posted a letter from his lawyer to Gary Gensler on social media, with the text "Gary, how could you do this to me" and a crying emoji. Alex spiro also asked in his letter who was directing the SEC's actions. Alex spiro emphasized that the SEC's "harassment" of Musk and its affiliates for six years has deviated from the original intention of seeking the truth and become an improper pressure. At present, the SEC has not commented on this. In addition, the letter said that the SEC also restarted the investigation of Neuralink, a brain-computer interface company owned by Musk. This autumn, the animal protection organization "Committee of Responsible Medical Doctors" and four US congressmen asked the SEC to investigate Neuralink, accusing it of securities fraud through misleading propaganda. (Securities Times)Governor of Poland's central bank: Poland will continue to achieve the CPI target.The US import price index in November was 1.3% year-on-year, expected to be 1%, and the previous value was 0.8%. The annual export price index of the United States in November was 0.8%, expected to be 0.3%, and the previous value was-0.10%.
Bei Ya raised Broadcom's target price from $195.00 to $210.00.On December 13th, Shaanxi Supervision Bureau of the State Financial Supervision and Administration issued an administrative penalty message showing that Baoji Central Branch of Ancheng Property Insurance Co., Ltd. was fined 60,000 yuan for giving benefits other than the insurance contract. The salesman of Baoji Central Branch of Ancheng Property Insurance Co., Ltd. was warned and fined 10,000 yuan.COMEX silver fell 2.00% in the day and is now quoted at $30.99 per ounce. COMEX silver fell to $31 per ounce, down 1.97% in the day.
Jinghe Jicheng: Shareholder Lijing Venture Capital intends to transfer 1.50% shares of the company by inquiry, and Jinghe Jicheng announced that shareholder Lijing Venture Capital intends to transfer 30.092 million shares of the company by inquiry transfer, accounting for 1.50% of the company's total share capital.US official-designate: The House panel will consider relaxing supervision and cryptocurrency structure. On Friday, Congressman Francci Hill, who will be the incoming chairman of the US House Financial Services Committee, said that the committee will focus on relaxing bank supervision, solving the problem of capital formation, so that more companies can go public, and solving the market structure of cryptocurrency. Hill also said in an interview that he has not yet decided whether the United States should establish a bitcoin reserve.Nearly 30 listed companies announced after-hours that their products would be selected, and the tenth batch of centralized drug procurement (centralized drug procurement) organized by the state was opened in Shanghai yesterday. According to incomplete statistics, as of press time, it includes Fuyuan Pharmaceutical, Yifan Pharmaceutical, ST Tiansheng, Hokuriku Pharmaceutical, Haizheng Pharmaceutical, Zhongheng Group, Yuandong Bio, Kelun Pharmaceutical, China Resources Shuanghe, Sinopharm Modern, Lingkang Pharmaceutical, Xuantai Pharmaceutical, Jiuzhou Pharmaceutical, Kang Enbei, Laimei Pharmaceutical, Kanghong Pharmaceutical, Huasen Pharmaceutical, Borui Pharmaceutical, Xianzeng Pharmaceutical. Among them, Kelun Pharmaceutical announced that 12 kinds of drugs, such as sodium acetate Ringer injection, sodium bicarbonate Ringer injection and gliclazide tablets, were to be selected.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14